Physician profile
Bert W Holmes
NPI 1881962645
$3,448.62
in general payments reported to CMS, 2019-2025
34 companies · $851 in 2025
The $851 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $83.63 · 2021: $386 · 2022: $356 · 2023: $469 · 2024: $1,108 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,384 · Education: $43.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,383.89 |
| Education | $43.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $757.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $475.65 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $387.81 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $198.03 | 2019-2025 | |
| Amgen INC. | $169.79 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $163.99 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $140.09 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $111.15 | 2023-2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.54 | 2019-2025 | Xifaxan |
| Abbott Laboratories | $94.33 | 2021-2025 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $86.66 | 2024 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.52 | 2023-2024 | Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $72.88 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $71.68 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Dynavax Technologies Corporation | $48.63 | 2023-2024 | Heplisav-B |
Show all 34 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bert Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.